Results 281 to 290 of about 249,915 (344)

Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri   +12 more
wiley   +1 more source

Single-Anesthesia Event for Lung Nodule Marking and Minimally Invasive Sublobar Resection. [PDF]

open access: yesJ Clin Med
Gordon N   +7 more
europepmc   +1 more source

Mono and combination therapies in pulmonary arterial hypertension patients with comorbidities: A COMPERA analysis

open access: yesESC Heart Failure, EarlyView.
AIM This analysis provides a comparison of the efficacy of initial mono and combination therapy in patients with PAH and cardiovascular comorbidities or with risk factors of HFpEF (heart failure with preserved ejection fractioin).METHOD Data from the European COMPERA registry were used for a matched pair analysis.
Dirk Skowasch   +20 more
wiley   +1 more source

Microaxial pump‐supported coronary surgery without CPB to optimize outcome in severely impaired left ventricles

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Cardiopulmonary bypass (CPB) is the standard approach for coronary artery bypass grafting (CABG) in advanced ischaemic cardiomyopathy. Microaxial pump support has been envisioned to allow for beating‐heart CABG without CPB (MPCAB), thereby avoiding CPB‐inherent complications.
Anna Kathrin Assmann   +5 more
wiley   +1 more source

Early administration of SGLT2 inhibitors in hospitalized patients: A practical guidance from the current evidence

open access: yesESC Heart Failure, EarlyView.
Abstract Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors represent one of the main cornerstones of heart failure treatment. Nevertheless, while the cardiovascular beneficial effects of these drugs have been clearly demonstrated by several clinical trials, in clinical practice, it remains challenging to identify the appropriate timing to start SGLT2 ...
Ruggero Mazzotta   +10 more
wiley   +1 more source

Right ventricular strain predicts outcome in patients receiving sacubitril/valsartan: A sub‐analysis of DISCOVER‐ARNI

open access: yesESC Heart Failure, EarlyView.
Angiotensin receptor/Neprilysin inhibitors (ARNI) have shown to considerably improve the clinical outcome of patients with heart failure and reduced ejection fraction (HFrEF). Identifying individuals who may benefit from ARNI the most could markedly enhance patient management.
Maria Concetta Pastore   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy